OpenURL Connection Search

Select item for more details and to access through your institution.

Energetic costs of mange in wolves estimated from infrared thermography.
Published in:
Ecology, 2016, v. 97, n. 8, p. 1938, doi. 10.1890/15-1346.1
By:
- CROSS, P. C.;
- ALMBERG, E. S.;
- HAASE, C. G.;
- HUDSON, P. J.;
- MALONEY, S. K.;
- METZ, M. C.;
- MUNN, A. J.;
- NUGENT, P.;
- PUTZEYS, O.;
- STAHLER, D. R.;
- STEWART, A. C.;
- SMITH, D. W.
Publication type:
Article
Borna disease virus RNA is absent in chronic multiple sclerosis.
Published in:
2001
By:
- Haase, Claus G.;
- Viazov, Sergei;
- Fiedler, Melanie;
- Koenig, Nikolaus;
- Faustmann, Pedro M.;
- Roggendorf, Michael;
- Haase, C G;
- Viazov, S;
- Fiedler, M;
- Koenig, N;
- Faustmann, P M;
- Roggendorf, M
Publication type:
Letter
Short-Term Cognitive Training Improves Mental Efficiency and Mood in Patients with Multiple Sclerosis.
Published in:
European Neurology, 2008, v. 60, n. 6, p. 304, doi. 10.1159/000157885
By:
- Brenk, A.;
- Laun, K.;
- Haase, C. G.
Publication type:
Article
Cognitive, but Not Mood Dysfunction Develops in Multiple Sclerosis during 7 Years of Follow-Up.
Published in:
European Neurology, 2004, v. 52, n. 2, p. 92, doi. 10.1159/000079937
By:
- Haase, C. G.;
- Tinnefeld, M.;
- Daum, I.;
- Ganz, R. E.;
- Haupts, M.;
- Faustmann, P. M.
Publication type:
Article
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Published in:
British Journal of Cancer, 2005, v. 92, n. 10, p. 1855, doi. 10.1038/sj.bjc.6602584
By:
- Awada, A.;
- Hendlisz, A.;
- Gil, T.;
- Bartholomeus, S.;
- Mano, M.;
- de Valeriola, D.;
- Strumberg, D.;
- Brendel, E.;
- Haase, C. G.;
- Schwartz, B.;
- Piccart, M.
Publication type:
Article

Found: 5

Energetic costs of mange in wolves estimated from infrared thermography.

Borna disease virus RNA is absent in chronic multiple sclerosis.

Short-Term Cognitive Training Improves Mental Efficiency and Mood in Patients with Multiple Sclerosis.

Cognitive, but Not Mood Dysfunction Develops in Multiple Sclerosis during 7 Years of Follow-Up.

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.